PL4010082T3 - Wieloswoiste przeciwciała anty-tcr zmienne delta 1 - Google Patents

Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Info

Publication number
PL4010082T3
PL4010082T3 PL21756070.5T PL21756070T PL4010082T3 PL 4010082 T3 PL4010082 T3 PL 4010082T3 PL 21756070 T PL21756070 T PL 21756070T PL 4010082 T3 PL4010082 T3 PL 4010082T3
Authority
PL
Poland
Prior art keywords
specific antibody
antibody anti
tcr variable
variable delta
delta
Prior art date
Application number
PL21756070.5T
Other languages
English (en)
Other versions
PL4010082T5 (pl
Inventor
Mark Uden
Mihriban Tuna
Natalie MOUNT
Robert Good
Joshua Freedman
Shefali BHUMBRA
Oliver Nussbaumer
Raj Jaysukhlal MEHTA
Original Assignee
GammaDelta Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4010082(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Application filed by GammaDelta Therapeutics Limited filed Critical GammaDelta Therapeutics Limited
Publication of PL4010082T3 publication Critical patent/PL4010082T3/pl
Publication of PL4010082T5 publication Critical patent/PL4010082T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
PL21756070.5T 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1 PL4010082T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (2)

Publication Number Publication Date
PL4010082T3 true PL4010082T3 (pl) 2023-05-29
PL4010082T5 PL4010082T5 (pl) 2026-03-09

Family

ID=80247426

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21756070.5T PL4010082T5 (pl) 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1
PL23187269.8T PL4269444T3 (pl) 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL23187269.8T PL4269444T3 (pl) 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Country Status (18)

Country Link
EP (7) EP4265642B1 (pl)
JP (1) JP2023537534A (pl)
KR (1) KR20230083267A (pl)
CN (1) CN116209456A (pl)
AU (1) AU2021323512A1 (pl)
BR (1) BR112023002741A2 (pl)
CA (1) CA3188682A1 (pl)
CO (1) CO2023003009A2 (pl)
DK (2) DK4269444T5 (pl)
ES (2) ES2943063T3 (pl)
FI (2) FI4010082T4 (pl)
IL (1) IL300517A (pl)
LT (2) LT4010082T (pl)
MX (1) MX2023001728A (pl)
PL (2) PL4010082T5 (pl)
PT (2) PT4269444T (pl)
SI (2) SI4010082T1 (pl)
WO (1) WO2022034562A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4265642B1 (en) 2020-08-14 2024-06-26 GammaDelta Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
EP4544302A1 (en) * 2022-06-23 2025-04-30 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
CN120677232A (zh) * 2023-03-17 2025-09-19 南京传奇生物科技有限公司 培养Vδ1 T细胞的方法
WO2025147597A1 (en) * 2024-01-05 2025-07-10 Eugit Therapeutics, Inc. Targeting payloads
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
CA2988050A1 (en) 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
JP6861418B2 (ja) * 2015-09-02 2021-04-28 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
ES2925261T3 (es) 2015-10-30 2022-10-14 Cancer Research Tech Ltd Expansión de células T gamma delta residentes en tejidos no hematopoyéticos y usos de estas células
EP3454870A4 (en) 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2018023111A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
CN111148761B (zh) 2017-06-25 2024-02-13 西雅图免疫公司 多特异性抗体及其制备和使用方法
US10519236B2 (en) 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
MX2021003234A (es) * 2018-09-19 2021-07-16 Lava Therapeutics N V Inmunoglobulina de la molecula cd1d de acción dual.
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
EP4434541A3 (en) * 2019-01-23 2025-02-26 New York University Antibodies specific to delta 1 chain of t cell receptor
BR112021015238A8 (pt) * 2019-02-01 2022-08-16 Lava Therapeutics B V Novos anticorpos de ligação a cd40
CA3136251A1 (en) 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
MX2022002075A (es) 2019-08-16 2022-03-17 Gammadelta Therapeutics Ltd Usos terapeuticos de anticuerpos anti-variable delta 1 de tcr.
US20220290101A1 (en) 2019-08-16 2022-09-15 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
EP4265642B1 (en) 2020-08-14 2024-06-26 GammaDelta Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
JP2024506682A (ja) 2021-02-17 2024-02-14 ガンマデルタ セラピューティクス リミテッド 抗ＴＣＲδ鎖可変部１抗体

Also Published As

Publication number Publication date
DK4010082T3 (da) 2023-04-03
EP4265643A3 (en) 2024-02-14
EP4269444A3 (en) 2024-02-14
EP4010082B2 (en) 2025-12-31
SI4010082T1 (sl) 2023-04-28
DK4010082T4 (en) 2026-02-16
EP4269445A2 (en) 2023-11-01
WO2022034562A1 (en) 2022-02-17
EP4265642B1 (en) 2024-06-26
CN116209456A (zh) 2023-06-02
AU2021323512A1 (en) 2023-04-13
LT4269444T (lt) 2024-09-25
EP4010082B9 (en) 2026-03-04
EP4010082B1 (en) 2023-01-25
JP2023537534A (ja) 2023-09-01
CO2023003009A2 (es) 2023-03-17
FI4010082T4 (fi) 2026-03-24
EP4269446A3 (en) 2024-02-14
MX2023001728A (es) 2023-04-20
EP4269444B1 (en) 2024-06-26
ES2943063T3 (es) 2023-06-08
EP4269445B1 (en) 2024-06-26
EP4269446B1 (en) 2024-06-26
IL300517A (en) 2023-04-01
FI4010082T3 (fi) 2023-04-04
EP4269444A2 (en) 2023-11-01
EP4269445A3 (en) 2024-02-14
EP4265643B1 (en) 2024-06-26
EP4218932A3 (en) 2023-09-27
EP4265642A3 (en) 2024-02-14
KR20230083267A (ko) 2023-06-09
EP4010082A1 (en) 2022-06-15
LT4010082T (lt) 2023-03-10
EP4218932A2 (en) 2023-08-02
EP4265643A2 (en) 2023-10-25
PL4269444T3 (pl) 2025-01-13
PT4010082T (pt) 2023-04-26
BR112023002741A2 (pt) 2023-10-10
FI4269444T3 (fi) 2024-09-20
DK4010082T5 (da) 2024-08-05
ES2993071T3 (en) 2024-12-20
CA3188682A1 (en) 2022-02-17
PL4010082T5 (pl) 2026-03-09
PT4269444T (pt) 2024-09-05
EP4269446A2 (en) 2023-11-01
DK4269444T3 (en) 2024-08-19
EP4265642A2 (en) 2023-10-25
SI4269444T1 (sl) 2024-10-30
DK4269444T5 (da) 2024-08-26

Similar Documents

Publication Publication Date Title
PL4010082T3 (pl) Wieloswoiste przeciwciała anty-tcr zmienne delta 1
IL290537A (en) Therapeutic uses of anti-tcr delta variable 1 antibodies
JP1750569S (ja) バックパック
IL284772A (en) Anti-variable muc1* antibodies and uses thereof
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
DK4214240T3 (da) Anti-ccr8-antistoffer
EP4196639A4 (en) VIBRATORY SCREED
IL311043A (en) Anti-il-11rα antibodies
EP4463485A4 (en) Tetrahedral antibodies
IL310245A (en) Anti-hla-g antibodies
EP4414388A4 (en) NEW ANTI-L1CAM ANTIBODY
EP4532558A4 (en) ANTI-ROR1 ANTIBODIES
EP4392455A4 (en) ANTI-CD-25 ANTIBODIES
EP4247426A4 (en) MULTISPECIFIC ANTI-GPA33 ANTIBODIES AND THEIR USES
ZA202308120B (en) Multispecific anti-tcr delta variable 1 antibodies
JP1769784S (ja) バックパック
EP4230079C0 (de) Schliesse
IL299767A (en) Anti-αlpha-4-βeta-7 antibodies
GB202111685D0 (en) Anti-tcr delta variable 1 antibodies
EP4471057A4 (en) ANTI-CXCL1 HUMAN ANTIBODY
JP1749982S (ja) バックパック
EP4453459C0 (de) Stellantrieb
DK4172199T3 (da) Alfa-synuklein-protofibril-bindende antistoffer
EP4323408A4 (en) NEW ANTI-HVEGFR2 ANTIBODIES
EP4268982A4 (en) ACTUATOR